CD5-positive and CD5-negative plaque-forming cells against poly-L-lysine-treated sheep erythrocytes in patients with systemic lupus erythematosus.
While attempting to evaluate CD5+ and CD5- anti-DNA-secreting plaque-forming cells (PFC) in patients with systemic lupus erythematosus (SLE), significant numbers of PFC against control sheep erythrocytes (ShE) treated with poly-L-lysine (PLL) but not further conjugated with single-stranded (ss) or double-stranded (ds) DNA were noted. Numbers of PFC obtained using PLL-ShE, ssDNA-ShE and dsDNA-ShE were not significantly different, all reactivity to DNA apparently being accounted for by binding of antibodies to PLL-treated ShE. Nevertheless, anti-PLL-PFC could be inhibited by soluble dsDNA included in the plaque assay. These findings might be explained by cationic anti-DNA antibodies binding non-specifically to anionic PLL. Control healthy subjects gave few PFC against PLL-ShE, ssDNA-ShE or dsDNA-ShE. Anti-PLL-PFC appeared to be related to disease activity, with higher numbers of both CD5+ and CD5- PFC in patients with clinically active SLE.
Jones
B M
BM
Department of Pathology, University of Hong Kong, Queen Mary Hospital.
Lau
C S
CS
Wong
R W
RW
D000293:Adolescent; D000328:Adult; D000818:Animals; D015703:Antigens, CD / Q000276:immunology*; D001323:Autoantibodies / Q000096:biosynthesis*; D001402:B-Lymphocytes / Q000276:immunology; D018956:CD5 Antigens; D004247:DNA / Q000276:immunology; D004277:DNA, Single-Stranded / Q000276:immunology; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006462:Hemolytic Plaque Technique; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011043:Pokeweed Mitogens / Q000276:immunology; D011107:Polylysine / Q000276:immunology*; D012756:Sheep; D013211:Staphylococcus aureus / Q000276:immunology
D015703:Antigens, CD; D001323:Autoantibodies; D018956:CD5 Antigens; D004277:DNA, Single-Stranded; D011043:Pokeweed Mitogens; D011107:Polylysine; D004247:DNA